Trials / Unknown
UnknownNCT00057369
Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections
Phase II, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections With Suspected or Confirmed Gram-Positive Bacterial Pathogens
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 88 (planned)
- Sponsor
- Vicuron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to evaluate a new medication dosed once a week in the treatment of bacterial infections in the blood from intravenous catheters (CR-BSI). The primary objective is to evaluate the efficacy and safety of dalbavancin in the treatment of adults with CR-BSI relative to a standard of care treatment, vancomycin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dalbavancin |
Timeline
- Start date
- 2001-02-01
- Completion
- 2003-06-01
- First posted
- 2003-04-02
- Last updated
- 2005-06-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00057369. Inclusion in this directory is not an endorsement.